vehicle foam

The vehicle foam is a proprietary, inactive topical delivery system developed by Vyne Therapeutics (formerly Foamix Pharmaceuticals) using its Molecule Stabilizing Technology (MST). It was utilized as the placebo control in clinical trials (such as FX2015-10 and FX2016-11) for Zilxi (FMX-103), a 1.5% minocycline foam indicated for the treatment of inflammatory lesions of papulopustular rosacea. The vehicle is designed to be a stable, non-irritating foam base containing moisturizing ingredients like coconut oil and soybean oil, but it lacks the active antibiotic ingredient, minocycline. Its primary purpose in drug development was to provide a baseline for safety and efficacy comparisons against the active minocycline formulation, helping to isolate the therapeutic effects of the drug from the properties of the foam carrier itself.

Other names

FMX-103 vehicleFMX103 vehicleFMX 103 vehicleminocycline vehicle foamMST vehicle foam